



## REVA to Hold Third Quarter 2017 Financial Results Call

**San Diego, California and Sydney, Australia** (Wednesday, 1 November 2017, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2017 financial results and provide a business update.

The call is scheduled for 9:00 a.m. AEDT on Wednesday, 8 November 2017 (which is 2:00 p.m. US PST on Tuesday, November 7, 2017) and may be accessed toll-free within Australia by dialing 1800 005 989 five minutes prior to the scheduled start time. Callers in the United States and Canada may access the call by dialing 1-877-312-5413. The conference ID is 1289896 for all locations.

If you reside outside of Australia, the United States, or Canada, or if you prefer to access the call through our website, please visit “Events & Presentations” under the “Investors” section of our website at [www.revamedical.com](http://www.revamedical.com), and click on the “listen to webcast” link. A live webcast of the call will also be available on our website.

### About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the *Fantom* bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

### About Fantom®

*Fantom* is a sirolimus-eluting bioresorbable scaffold (BRS) developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. *Fantom* is the only bioresorbable scaffold made from Tyrocore™, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making *Fantom* the first and only BRS that is visible under fluoroscopy. *Fantom* is designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.

**United States  
Investor & Media Enquiries:**  
REVA Medical, Inc.  
Brandi Roberts  
Chief Financial Officer  
+1 858-966-3003  
Cheryl Liberatore  
Director, Communications  
+1 858-966-3045  
[ir@revamedical.com](mailto:ir@revamedical.com)

**Australia  
Investor Enquiries:**  
Inteq Limited  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia  
Media Enquiries:**  
Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722

---

**HEAD OFFICE:** 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • [www.revamedical.com](http://www.revamedical.com)

**AUSTRALIAN OFFICE:** Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

---